Frazier Life Sciences Management, L.P.: KRYSTAL BIOTECH (KRYS): Quarterly 13F Position History
As of Q1 2026, Frazier Life Sciences Management, L.P. reported 481,307 shares of KRYSTAL BIOTECH (KRYS), worth $124.3M and representing 3.2% of its 13F equity book. Quarter-over-quarter share count change: 7,153 (-1.5%) . The position first appeared in Q1 2022 and has been disclosed across 17 13F-HR filings in Pactolio's tracked window.
- 481,307Shares Held (Latest Filing)
- $124.3MReported Market Value (Latest Filing)
- 3.2%Portfolio Weight (% of 13F Equity Book)
- 7,153Quarter-over-Quarter Share Change
- +$3.9MQuarter-over-Quarter Value Change
- 1,095,407Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 17 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 481,307 | 7,153 | -1.5% | $124.3M | 3.2% | $258.3 |
| Q4 2025 | 488,460 | 200,000 | -29.1% | $120.4M | 3.2% | $246.5 |
| Q3 2025 | 688,460 | 0 | — | $121.5M | 3.6% | $176.5 |
| Q2 2025 | 688,460 | 0 | — | $94.6M | 3.8% | $137.5 |
| Q1 2025 | 688,460 | 100,000 | -12.7% | $124.1M | 5.7% | $180.3 |
| Q4 2024 | 788,460 | 200,000 | -20.2% | $123.5M | 5.1% | $156.7 |
| Q3 2024 | 988,460 | 0 | — | $179.9M | 7.2% | $182.0 |
| Q2 2024 | 988,460 | 0 | — | $181.5M | 8.5% | $183.6 |
| Q1 2024 | 988,460 | 0 | — | $175.9M | 7.4% | $177.9 |
| Q4 2023 | 988,460 | 0 | — | $122.6M | 6.6% | $124.1 |
| Q3 2023 | 988,460 | 1,800 | -0.2% | $114.7M | 7.6% | $116.0 |
| Q2 2023 | 990,260 | +44,853 | +4.7% | $116.3M | 6.9% | $117.4 |
| Q1 2023 | 945,407 | 54,330 | -5.4% | $75.7M | 5.5% | $80.1 |
| Q4 2022 | 999,737 | 18,651 | -1.8% | $79.2M | 4.9% | $79.2 |
| Q3 2022 | 1,018,388 | 77,019 | -7.0% | $71.0M | 5.5% | $69.7 |
| Q2 2022 | 1,095,407 | +229,157 | +26.5% | $71.9M | 6.8% | $65.7 |
| Q1 2022 | 866,250 | — | — | $57.6M | 4.9% | $66.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Frazier Life Sciences Management, L.P. first disclose a KRYS position in 13F-HR filings?
Frazier Life Sciences Management, L.P. first reported KRYSTAL BIOTECH (KRYS) on its 13F-HR filing for the period ending 2022-03-31 (Q1 2022). The position has appeared on 17 reported quarters within Pactolio's tracked window.
What was Frazier Life Sciences Management, L.P.'s most recent quarter-over-quarter share-count change in KRYS?
Between Q4 2025 and Q1 2026, Frazier Life Sciences Management, L.P. reduced its KRYS position by 7,153 shares (-1.5%), leaving 481,307 shares at a market value of $124.3M.
Does the implied price-per-share represent Frazier Life Sciences Management, L.P.'s cost basis in KRYS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.